Volume 95, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Although convalescent plasma (CP) transfusion was prioritized among potential Ebola treatments by the World Health Organization, there were concerns on the feasibility of its implementation. We report on the successful organization of donor mobilization and plasma collection as part of the Ebola-Tx clinical trial from November 2014 to July 2015 in Conakry, Guinea. Project implementation registers, tools and reports, mission reports, and minutes of research team meetings were used to reconstruct the sequence of events on how donor mobilization was organized, plasmapheresis was set up, and how effective this approach was in collecting CP. An initial needs assessment of the Guinean National Blood Transfusion Center resulted in targeted training of staff on site, resulting in autonomy and independent production of CP within 3 months. The Conakry Ebola Survivors Association played a direct role in donor mobilization and organization of CP donations. A total of 98 Ebola survivors were screened for plasma donation, of which 84 were found eligible for plasmapheresis. Of these, 26 (30.9%) were excluded. The remaining 58 donors made a total of 90 donations, corresponding to 50.9 L of CP. This sufficed to treat the 99 eligible patients enrolled in the trial. Within a poor resource emergency context, transfusion capacity could be rapidly improved through the strengthening of local capacities and gradual transfer of skills coupled with active involvement of Ebola survivors. However, large-scale plasma collection or multisite studies may require further adaptations of both strategy and logistics. The Ebola-Tx trial was funded by the European Union and others.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. WHO Ebola Response Team, 2014. Ebola virus disease in west Africa–the first 9 months of the epidemic and forward projections. N Engl J Med 371: 14811495.[Crossref] [Google Scholar]
  2. World Health Organization, 2015. Statement on the WHO Consultation on Potential Ebola Therapies and Vaccines. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/mediacentre/news/statements/2014/ebola-therapies-consultation/en/. Accessed May 19, 2015. [Google Scholar]
  3. Gulland A, , 2014. First Ebola treatment is approved by WHO. BMJ 349: g5539.[Crossref] [Google Scholar]
  4. World Health Organization, 2015. Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment During Outbreaks. Interim guidance for national health authorities and blood transfusion services. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/. Accessed May 19, 2015. [Google Scholar]
  5. Bannister-Tyrrell M, Gryseels C, Delamou A, D'Alessandro U, van Griensven J, Grietens KP, Tx Trial Platform, , 2015. Blood as medicine: social meanings of blood and the success of Ebola trials. Lancet 385: 420.[Crossref] [Google Scholar]
  6. Nielsen CF, Kidd S, Sillah AR, Davis E, Mermin J, Kilmarx PH, , 2015. Improving burial practices and cemetery management during an Ebola virus disease epidemic–Sierra Leone, 2014. MMWR Morb Mortal Wkly Rep 64: 2027. [Google Scholar]
  7. Thiam S, Delamou A, Camara S, Carter J, Lama EK, Ndiaye B, Nyagero J, Nduba J, Ngom M, , 2015. Challenges in controlling the Ebola outbreak in two prefectures in guinea: why did communities continue to resist? Pan Afr Med J 22 (Suppl 1): 22. [Google Scholar]
  8. Colebunders RL, Cannon RO, , 2015. Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease. J Infect Dis 211: 12081210. [Google Scholar]
  9. Noubiap JJ, Joko WY, Nansseu JR, Tene UG, Siaka C, , 2013. Sero-epidemiology of human immunodeficiency virus, hepatitis B and C viruses, and syphilis infections among first-time blood donors in Edéa, Cameroon. Int J Infect Dis 17: e832e837.[Crossref] [Google Scholar]
  10. Lund TC, Hume H, Allain JP, McCullough J, Dzik W, , 2013. The blood supply in Sub-Saharan Africa: needs, challenges, and solutions. Transfus Apheresis Sci 49: 416421.[Crossref] [Google Scholar]
  11. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze J, Ravinetto R, Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, Weggheleire AD, Haba N, for the Ebola-Tx Consortium , 2016. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 374: 3342.[Crossref] [Google Scholar]
  12. WHO, 2015. Community Engagement and Education, Recruitment and Retention of People Recovered from Ebola as Potential Blood Donors for Convalescent Whole Blood and Plasma. Interim guidance for National Health Authorities, Blood Transfusion Services and Researchers. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/bloodsafety/interim-guidance_CWB-CP.pdf. Accessed July 16, 2015. [Google Scholar]
  13. Falero F, , 2015. Rapid Evaluation of Convalescent Blood and Plasma and Favipiravir Therapies for Ebola Virus Disease (EVD) in Guinea. Conakry, Guinea: Médecins Sans Frontières. [Google Scholar]
  14. Ali R, Finlayson A, Indox Cancer Research Network, , 2012. Building capacity for clinical research in developing countries: the INDOX Cancer Research Network experience. Glob Health Action 5: doi:10.3402/gha.v5i0.17288. [Google Scholar]
  15. Enserink M, , 2015. Infectious diseases. Ebola survivors fight back in plasma studies. Science 348: 742743.[Crossref] [Google Scholar]
  16. Burnouf T, Emmanuel J, Mbanya D, El-Ekiaby M, Murphy W, Field S, Allain JP, , 2014. Ebola: a call for blood transfusion strategy in sub-Saharan Africa. Lancet 384: 13471348.[Crossref] [Google Scholar]
  17. van Griensven J, De Weiggheleire A, Delamou A, Smith PG, Edwards T, Vandekerckhove P, Bah EI, Colebunders R, Herve I, Lazaygues C, Haba N, Lynen L, , 2015. The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings: a perspective from the field. Clin Infect Dis 62: 6974.[Crossref] [Google Scholar]
  18. Tagny CT, Mbanya D, Tapko JB, Lefrere JJ, , 2008. Blood safety in sub-Saharan Africa: a multi-factorial problem. Transfusion 48: 12561261.[Crossref] [Google Scholar]
  19. Coordination Nationale Ebola in Guinée, OMS, 2015. Rapport de la Situation Epidémiologique, Maladie à Virus Ebola en Guinée du 31 Mars 2015. Sit_Rep_no 350. Conakry, Guinea: Coordination Nationale Ebola Guinée and Organisation Mondiale de la Santé. Available at: http://guinea-ebov.github.io/. Assessed on July 10, 2015. [Google Scholar]
  20. Wong HK, Lee CK, Hung IF, Leung JN, Hong J, Yuen KY, Lin CK, , 2010. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion 50: 19671971.[Crossref] [Google Scholar]
  21. Bagot KL, Bove LL, Masser BM, Bednall TC, Buzza M, , 2013. Perceived deterrents to being a plasmapheresis donor in a voluntary, non-remunerated environment. Transfusion 53: 11081119.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 10 Dec 2015
  • Accepted : 06 May 2016
  • Published online : 07 Sep 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error